Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma

by Milind Javle, Maeve Lowery, Rachna T. Shroff, Karl Heinz Weiss, Christoph Springfeld, Mitesh J. Borad, Ramesh K. Ramanathan, Lipika Goyal, Saeed Sadeghi, Teresa Macarulla, Anthony El-Khoueiry, Robin Kate Kelley, Ivan Borbath, Su Pin Choo, Do Youn Oh, Philip A. Philip, Li Tzong Chen, Thanyanan Reungwetwattana, Eric Van Cutsem, Kun Huei Yeh, Kristen Ciombor, Richard S. Finn, Anuradha Patel, Suman Sen, Dale Porter, Randi Isaacs, Andrew X. Zhu, Ghassan K. Abou-Alfa, Tanios Bekaii-Saab
Published 2019

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

by Daniel V. T. Catenacci, Yoon-Koo Kang, Hope E. Uronis, Keun-Wook Lee, Matthew C. H. Ng, Peter C. Enzinger, Se Hoon Park, Philip J. Gold, Jill Lacy, Howard S. Hochster, Sang Cheul Oh, Yeul Hong Kim, Kristen A. Marrone, Ronan J. Kelly, Rosalyn A. Juergens, Jong Gwang Kim, Thierry Alcindor, Sun Jin Sym, Eun-Kee Song, Cheng Ean Chee, Yee Chao, Sunnie Kim, Do-Youn Oh, Jennifer Yen, Justin I. Odegaard, Errin Lagow, Daner Li, Jichao Sun, Patrick Kaminker, Paul A. Moore, Minori Koshiji Rosales, Haeseong Park
Published 2023